Vol. 2 No. 5 (2022): May
Reimbursement Reviews

Somatrogon (Ngenla)

Published May 11, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses somatrogon (Ngenla), 24 mg/1.2 mL (20 mg/mL) as a pre-filled pen or 60 mg/1.2 mL (50 mg/mL) as a pre-filled pen for SC injection.
  • Indication: The long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency).